newsfilter
← Latest News
Business Wire·

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference

New interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that five